MCID: BRN028
MIFTS: 73

Brain Cancer

Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Brain Cancer

MalaCards integrated aliases for Brain Cancer:

Name: Brain Cancer 12 54 15
Malignant Neoplasm of Brain 29 70 32
Adult Brain Tumor 12 54 70
Brain Neoplasms 73 44 70
Primary Malignant Neoplasm of Brain 12 70
Neoplasm of Brain 12 6
Brain Neoplasm 12 17
Brain Tumors 54 42
Malignant Primary Brain Neoplasm 12
Adult Malignant Brain Neoplasm 12
Malignant Tumor of Adult Brain 12
Malignant Primary Brain Tumors 54
Malignant Primary Brain Tumor 12
Malignant Tumor of Brain 12
Malignant Brain Tumour 12
Primary Brain Neoplasm 12
Brain Neoplasm, Adult 12
Primary Brain Tumors 15
Brain Tumor, Primary 70
Primary Brain Tumor 12
Brain Tumor Primary 54
Tumor of the Brain 12
Brain Tumor, Adult 20
Bt - Brain Tumour 12
Cancer, Brain 39

Classifications:



External Ids:

Disease Ontology 12 DOID:1319
ICD9CM 34 191 239.6
MeSH 44 D001932
ICD10 32 C71 C71.9
UMLS 70 C0006118 C0153633 C0220624 more

Summaries for Brain Cancer

MedlinePlus : 42 A brain tumor is a growth of abnormal cells in the tissues of the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Some are primary brain tumors, which start in the brain. Others are metastatic, and they start somewhere else in the body and move to the brain. Brain tumors can cause many symptoms. Some of the most common are Headaches, often in the morning Nausea and vomiting Changes in your ability to talk, hear, or see Problems with balance or walking Problems with thinking or memory Feeling weak or sleepy Changes in your mood or behavior Seizures Doctors diagnose brain tumors by doing a neurologic exam and tests including an MRI, CT scan, and biopsy. Treatment options include watchful waiting, surgery, radiation therapy, chemotherapy, and targeted therapy. Targeted therapy uses drugs or other substances that attack cancer cells with less harm to normal cells. Many people get a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Brain Cancer, also known as malignant neoplasm of brain, is related to li-fraumeni syndrome and tuberous sclerosis, and has symptoms including seizures, tremor and back pain. An important gene associated with Brain Cancer is MIR142 (MicroRNA 142), and among its related pathways/superpathways are ERK Signaling and Activation of cAMP-Dependent PKA. The drugs Sevoflurane and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and eye, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.

Wikipedia : 73 A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors:... more...

Related Diseases for Brain Cancer

Diseases related to Brain Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 953)
# Related Disease Score Top Affiliating Genes
1 li-fraumeni syndrome 32.8 TP53 PTEN IDH2 IDH1 EGFR CTNNB1
2 tuberous sclerosis 32.3 TP53 PTEN PIK3CA NES
3 brain glioma 32.2 TP53 NES MGMT IDH2 IDH1 EGFR
4 gliomatosis cerebri 32.1 TP53 PTEN NES IDH1 EGFR BRAF
5 medulloblastoma 32.1 TP53 PTEN PIK3CA NRAS NES MGMT
6 supratentorial cancer 32.1 TP53 NES MGMT IDH1 EGFR
7 atypical teratoid rhabdoid tumor 32.1 TP53 MIR142 IDH1 H3-3A CTNNB1 ALK
8 infratentorial cancer 32.0 TP53 PTEN NES MIR25 MIR142 MGMT
9 glioblastoma 31.7 TP53 PTEN PIK3R1 PIK3CA NRAS NES
10 lung cancer 31.7 TP53 PTPN11 PTEN PIK3R1 PIK3CA NRAS
11 glioma 31.6 TP53 PTEN PIK3CA MIR25 IDH2 IDH1
12 adenoma 31.5 TP53 PIK3CA MGMT CTNNB1 BRAF
13 glioma susceptibility 1 31.4 TP53 IDH2 IDH1 H3-3A DANCR
14 malignant astrocytoma 31.3 TP53 PTEN NES MIR142 MGMT IDH2
15 high grade glioma 31.3 TP53 PTEN PIK3CA NES MGMT IDH2
16 high grade ependymoma 31.1 TP53 MGMT IDH1 H3-3A EGFR
17 adenocarcinoma 31.1 TP53 PTEN PIK3CA EGFR CTNNB1 BRAF
18 oligodendroglioma 31.1 TP53 PTEN MGMT IDH2 IDH1 EGFR
19 brain stem glioma 31.0 TP53 PIK3CA IDH2 IDH1 H3-3A EGFR
20 meningioma, familial 31.0 TP53 PTPN11 PTEN PIK3R1 PIK3CA EGFR
21 childhood medulloblastoma 31.0 TP53 EGFR CTNNB1
22 low grade glioma 30.9 MGMT IDH2 IDH1
23 small cell carcinoma 30.9 TP53 PTEN EGFR ALK
24 neurofibroma 30.9 TP53 PTEN EGFR
25 gemistocytic astrocytoma 30.9 TP53 PTEN IDH2 IDH1
26 basal cell nevus syndrome 30.9 TP53 PTEN EGFR CTNNB1
27 neuroblastoma 30.9 TP53 PTPN11 PTEN PIK3CA NRAS NES
28 teratoma 30.9 TP53 PTEN NES CTNNB1
29 cerebral ventricle cancer 30.9 TP53 NES MGMT IDH1 EGFR
30 central nervous system benign neoplasm 30.9 TP53 PTEN IDH1 H3-3A CTNNB1
31 frontal lobe neoplasm 30.9 TP53 MGMT IDH1 EGFR
32 astroblastoma 30.9 NES IDH1 BRAF
33 cellular ependymoma 30.8 NES MGMT EGFR
34 anaplastic astrocytoma 30.8 TP53 PTEN NES MGMT IDH2 IDH1
35 renal cell carcinoma, nonpapillary 30.8 TP53 PTEN PIK3CA NRAS MIR142 EGFR
36 intrahepatic cholangiocarcinoma 30.8 TP53 IDH2 IDH1 EGFR CTNNB1
37 nervous system cancer 30.8 TP53 MIR25 MIR142 MGMT IDH1 EGFR
38 pleomorphic xanthoastrocytoma 30.7 TP53 MGMT IDH1 H3-3A BRAF
39 pilomyxoid astrocytoma 30.7 IDH1 H3-3A BRAF
40 central nervous system cancer 30.7 TP53 PTEN NES MIR142 MGMT IDH2
41 cholangiocarcinoma 30.7 TP53 PIK3CA IDH2 IDH1 EGFR CTNNB1
42 hemangioma 30.7 TP53 PTEN IDH2 IDH1 CTNNB1
43 carcinosarcoma 30.7 TP53 PTEN PIK3CA EGFR CTNNB1
44 temporal lobe neoplasm 30.7 MGMT IDH1
45 myelodysplastic syndrome 30.7 TP53 PTPN11 PTEN NRAS MGMT IDH2
46 transitional cell carcinoma 30.7 TP53 PTEN EPHB2 EGFR BRAF
47 anaplastic oligodendroglioma 30.6 MGMT IDH2
48 giant cell glioblastoma 30.6 TP53 PTEN PIK3R1 PIK3CA NRAS MGMT
49 pilocytic astrocytoma 30.6 TP53 PTPN11 PTEN PIK3CA NRAS NES
50 suppression of tumorigenicity 12 30.6 TP53 PTEN PIK3CA IDH1 EGFR CTNNB1

Comorbidity relations with Brain Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Edema
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Hypertension, Essential
Obstructive Hydrocephalus Schizophreniform Disorder

Graphical network of the top 20 diseases related to Brain Cancer:



Diseases related to Brain Cancer

Symptoms & Phenotypes for Brain Cancer

UMLS symptoms related to Brain Cancer:


seizures; tremor; back pain; headache; syncope; pain; chronic pain; sciatica; vertigo/dizziness; sleeplessness

GenomeRNAi Phenotypes related to Brain Cancer according to GeneCards Suite gene sharing:

26 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.19 EGFR PIK3CA
2 Decreased viability GR00055-A-2 10.19 EGFR PIK3CA
3 Decreased viability GR00221-A-1 10.19 ALK EGFR NRAS PIK3CA PIK3R1
4 Decreased viability GR00221-A-2 10.19 PIK3CA
5 Decreased viability GR00221-A-3 10.19 NRAS PIK3R1
6 Decreased viability GR00221-A-4 10.19 ALK EGFR PIK3CA
7 Decreased viability GR00249-S 10.19 ALK
8 Decreased viability GR00402-S-2 10.19 PIK3CA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.15 PIK3R1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-112 10.15 IDH1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.15 IDH1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.15 IDH1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.15 IDH1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.15 BRAF
15 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.15 IDH2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.15 IDH1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.15 IDH2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.15 IDH2 PIK3R1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.15 PTPN11
20 Increased shRNA abundance (Z-score > 2) GR00366-A-18 10.15 IDH1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.15 IDH2 PIK3R1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.15 PIK3R1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-216 10.15 IDH2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-27 10.15 IDH2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.15 PIK3R1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.15 IDH1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.15 IDH2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.15 PIK3R1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.15 BRAF CTNNB1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.15 PIK3CA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.15 PTPN11
32 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.15 IDH2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.15 PTPN11
34 Decreased cell migration GR00055-A-1 9.72 ALK EPHB2
35 Decreased cell migration GR00055-A-3 9.72 BRAF EGFR PIK3CA
36 Reduced mammosphere formation GR00396-S 9.17 BRAF EGFR IDH2 NRAS PIK3R1 PTEN
37 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.85 CTNNB1

MGI Mouse Phenotypes related to Brain Cancer:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.3 ALK BRAF CTNNB1 EGFR EPHB2 MGMT
2 integument MP:0010771 10.21 ALK BRAF CTNNB1 EGFR NRAS PIK3CA
3 neoplasm MP:0002006 10.21 ALK BRAF CTNNB1 EGFR IDH2 MGMT
4 digestive/alimentary MP:0005381 10.14 BRAF CTNNB1 EGFR EPHB2 NRAS PTEN
5 limbs/digits/tail MP:0005371 10.1 BRAF CTNNB1 EGFR IDH2 NRAS PTEN
6 liver/biliary system MP:0005370 10.08 BRAF CTNNB1 EGFR NRAS PIK3R1 PTEN
7 muscle MP:0005369 10.06 BRAF CTNNB1 EGFR PIK3CA PIK3R1 PTEN
8 normal MP:0002873 10.02 ALK BRAF CTNNB1 EGFR NRAS PIK3R1
9 reproductive system MP:0005389 9.96 ACRBP ALK BRAF CTNNB1 EGFR EPHB2
10 no phenotypic analysis MP:0003012 9.95 CTNNB1 EGFR MGMT NRAS PIK3CA PTPN11
11 pigmentation MP:0001186 9.92 ALK BRAF CTNNB1 EGFR NRAS PTEN
12 respiratory system MP:0005388 9.81 ALK BRAF CTNNB1 EGFR IDH1 MGMT
13 skeleton MP:0005390 9.7 ALK BRAF CTNNB1 EGFR IDH1 IDH2
14 vision/eye MP:0005391 9.36 ALK BRAF CTNNB1 EGFR EPHB2 NRAS

Drugs & Therapeutics for Brain Cancer

Drugs for Brain Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 508)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
4
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Ephedrine Approved Phase 4 299-42-3 9294
7
Phenylephrine Approved Phase 4 59-42-7 6041
8
Pseudoephedrine Approved Phase 4 90-82-4 7028
9
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
10
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
11
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
12
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
13
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
14
Thrombin Approved, Investigational Phase 4
15
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
16
Clevidipine Approved, Investigational Phase 4 167221-71-8
17
Labetalol Approved Phase 4 36894-69-6 3869
18
Hydralazine Approved Phase 4 86-54-4 3637
19
Levetiracetam Approved Phase 4 102767-28-2 441341
20
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
21
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
22
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
23
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
24
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
25
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
26
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
27
Amitriptyline Approved Phase 4 50-48-6 2160
28
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
29
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
30
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
31
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
32
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
33
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
34
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
35
Propranolol Approved, Investigational Phase 4 525-66-6 4946
36
Topiramate Approved Phase 4 97240-79-4 5284627
37
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
38
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
39
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
40
Racepinephrine Approved Phase 4 329-65-7 838
41
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
42
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
43
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
44 Cytochrome P-450 CYP3A Inhibitors Phase 4
45 Cytochrome P-450 Enzyme Inhibitors Phase 4
46 Central Nervous System Stimulants Phase 4
47 Narcotics Phase 4
48 Analgesics, Opioid Phase 4
49 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Phase 4
50 Calcium, Dietary Phase 4

Interventional clinical trials:

(show top 50) (show all 1221)
# Name Status NCT ID Phase Drugs
1 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
2 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
3 A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
4 Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
5 Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study) Completed NCT00571155 Phase 4 levetiracetam
6 Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
7 A Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Metastatic Brain Tumors Completed NCT00075166 Phase 4
8 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
9 Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery Completed NCT02964416 Phase 4 Injection Tramadol
10 The Effect of Dexmedetomidine as an Adjuvant to General Anesthesia on Intelligence Development in Pediatric Patients Undergoing Craniotomy: a Randomized, Double-blind and Placebo-controlled Pilot Trial Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
11 Effective and Safe Morphine Dose for Patient Controlled Anesthesia in Supratentorial Craniotomies Completed NCT04313374 Phase 4 Morphine PCA 1 mg;Morphine PCA 0,5 mg;Placebo
12 Influence of Vasopressors on Brain Oxygenation and Microcirculation in Anesthetized Patients With Cerebral Tumors Completed NCT02713087 Phase 4 Ephedrine;Phenylephrine
13 A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
14 The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block: A Randomized Controlled Trial Completed NCT02558569 Phase 4 Levobupivacaine
15 The Effect of Intravenous Single Dose of Magnesium Sulphate on Attenuation of Hemodynamic Pressor Response After Myfield's Clamp Application During Craniotomies Completed NCT03318471 Phase 4 MgSo4;0.9% NaCl
16 Sugammadex Given for the Reversal of Deep Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants: A Retrospective Study Completed NCT02708056 Phase 4 Sugammadex
17 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
18 Impact of Prophylactic Use of Dexmedetomidine on Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor: a Pilot Randomized Controlled Trial Completed NCT04494828 Phase 4 Dexmedetomidine;Normal saline group
19 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
20 Validation and Verification of 3 Dimensional Laparoscopic System in Laparoscopic Distal Pancreatectomy & Splenectomy Completed NCT02757690 Phase 4
21 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
22 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
23 The Effect of Pre-incisional Anterior Scalp Block on Intraoperative Opioid Consumption in Adult Patients Undergoing Elective Craniotomy to Remove Tumor: A Prospective Randomized Controlled Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
24 Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome of Patients Undergoing Brain Tumor Exclusion Recruiting NCT04266665 Phase 4 Dexmedetomidine
25 Gemini - Cancer Genetic Testing in Ethnic Populations Recruiting NCT04475640 Phase 4
26 A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial Active, not recruiting NCT02334722 Phase 4 Levetiracetam extended release
27 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
28 Dexmedetomidine for Prevention of Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor: a Multicenter Randomized Controlled Trial Not yet recruiting NCT04399343 Phase 4 Dexmedetomidine;Normal saline
29 Effects of Pre-emptive Scalp Infiltration With Ketorolac and Ropivacaine for Postoperative Pain Relief After Elective Supratentorial Craniotomy (PAINLESS) Not yet recruiting NCT04141319 Phase 4 Ketorolac;Ropivacaine;Epinephrine
30 Phase IV GliaSite® Radiation Therapy System Registry Protocol for the Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
31 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
32 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
33 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
34 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
35 Role of 3-D Navigable Ultrasound in Resection of Intra-axial Brain Tumors - A Randomized Controlled Study Unknown status NCT02150564 Phase 3
36 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
37 Proteome-based Personalized Immunotherapy of Malignant Brain Tumors Unknown status NCT01759810 Phase 2, Phase 3
38 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
39 Gefitinib Alone or With Concomitant Whole Brain Radiotherapy for Patients Harboring an EGFR Mutation With Multiple Brain Metastases From Non-Small-cell Lung Cancer: a Phase II/III Randomized Controlled Trial Unknown status NCT02338011 Phase 2, Phase 3 Gefitinib
40 Phase 3 Study of Stereotactic Radiotherapy of the Postoperative Resection Cavity Versus Whole-Brain Irradiation After Surgical Resection of Single Brain Metastasis Unknown status NCT01535209 Phase 3
41 A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis Unknown status NCT02460068 Phase 3 Fotemustine;Fotemustine and Ipilimumab;Ipilimumab and nivolumab
42 Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures Unknown status NCT02563288 Phase 3 Esmolol;Dexmedetomidine
43 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
44 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
45 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
46 Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
47 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
48 Intra-individual Comparison Study of Intravenously Administered Magnevist (SH L 451A) on Lesion Detection Ability in MRI After an Initial Dose of 0.1 mmol/kg and After an Additional Dose of 0.1 mmol/kg in Patients With Metastatic Brain Tumor Completed NCT00681551 Phase 3 Magnevist (SH L 451A);Magnevist (SH L 451A)
49 Randomized Phase III Trial of Postoperative Whole Brain Radiation Therapy Compared With Salvage Stereotactic Radiosurgery in Patients With One to Four Brain Metastasis: Japan Clinical Oncology Group Study (JCOG 0504) Completed NCT00280475 Phase 3
50 A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer Completed NCT00123760 Phase 2, Phase 3

Search NIH Clinical Center for Brain Cancer

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carmustine
Etoposide
etoposide phosphate
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Lomustine
Mifepristone
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cochrane evidence based reviews: brain neoplasms

Genetic Tests for Brain Cancer

Genetic tests related to Brain Cancer:

# Genetic test Affiliating Genes
1 Malignant Neoplasm of Brain 29

Anatomical Context for Brain Cancer

MalaCards organs/tissues related to Brain Cancer:

40
Brain, Breast, Eye, T Cells, Endothelial, Cortex, Bone

Publications for Brain Cancer

Articles related to Brain Cancer:

(show top 50) (show all 4110)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
2
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
3
Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients. 6
24721394 2014
4
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. 6
23558169 2013
5
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. 6
22586120 2012
6
Targeted therapy for BRAFV600E malignant astrocytoma. 6
22038996 2011
7
Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. 6
22072639 2011
8
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. 6
17177598 2006
9
PTEN controls tumor-induced angiogenesis. 6
11274365 2001
10
Risk factors for brain metastases from non-small-cell lung cancer: A protocol for observational study. 42
33655937 2021
11
Maximal tumor diameter in the preoperative tumor magnetic resonance imaging (MRI) T2 image is associated with prognosis of Grade II Glioma. 42
33725839 2021
12
Reminiscence therapy-based care program for reducing anxiety and depression in glioma survivors: A randomized controlled trial. 42
33592815 2021
13
Survey of MicroRNA expression in pediatric brain tumors. 47
21157891 2011
14
FasL gene knock-down therapy enhances the antiglioma immune response. 61 54
20406899 2010
15
Mig-6 controls EGFR trafficking and suppresses gliomagenesis. 61 54
20351267 2010
16
MRI-coupled fluorescence tomography quantifies EGFR activity in brain tumors. 54 61
20152724 2010
17
CMDS: a population-based method for identifying recurrent DNA copy number aberrations in cancer from high-resolution data. 61 54
20031968 2010
18
A review of studies on targeting interleukin 4 receptor for central nervous system malignancy. 54 61
19689300 2009
19
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. 61 54
19333229 2009
20
Therapeutic targeting of g-protein coupled receptor-mediated epidermal growth factor receptor transactivation in human glioma brain tumors. 54 61
18991757 2008
21
Somatic alterations in brain tumors. 54 61
18575738 2008
22
Gene expression profiling of metastatic brain cancer. 61 54
17611651 2007
23
Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. 61 54
17679463 2007
24
Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. 61 54
17483310 2007
25
Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. 54 61
17440072 2007
26
Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. 61 54
17172420 2006
27
New roles for galectins in brain tumors--from prognostic markers to therapeutic targets. 61 54
15912884 2005
28
RNA interference and nonviral targeted gene therapy of experimental brain cancer. 61 54
15717065 2005
29
Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. 54 61
15173073 2004
30
Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors. 54 61
12540498 2003
31
Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-co-glycolide) microsphere formulations for potential combination therapy in cancer. 54 61
11839444 2002
32
Ethnicity delineates different genetic pathways in malignant glioma. 61 54
11358811 2001
33
Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. 54 61
8700129 1996
34
Development of L-carnosine functionalized iron oxide nanoparticles loaded with dexamethasone for simultaneous therapeutic potential of blood brain barrier crossing and ischemic stroke treatment. 61
33586561 2021
35
Gradient hydrogels for screening stiffness effects on patient-derived glioblastoma xenograft cellfates in 3D. 61
32862485 2021
36
Past, present and future, the experience of time during examination for malignant brain tumor: a qualitative observational study. 61
33389116 2021
37
Recent advances in iron oxide nanoparticles for brain cancer theranostics: from in vitro to clinical applications. 61
33567919 2021
38
Visual enhancement of brain cancer MRI using multiscale dyadic filter and Hilbert transformation. 61
32776890 2021
39
Metabolic Vulnerabilities in Brain Cancer. 61
33781499 2021
40
Increasing emergency department utilization of brain imaging in patients with primary brain cancer. 61
32803458 2021
41
Pre-clinical investigation of mesenchymal stromal cell-derived extracellular vesicles: a systematic review. 61
33541780 2021
42
Human TERT promoter mutations as a prognostic biomarker in glioma. 61
33547950 2021
43
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. 61
33601293 2021
44
Conformable hierarchically engineered polymeric micromeshes enabling combinatorial therapies in brain tumours. 61
33795849 2021
45
Risk of Cancer in Long-Term Levothyroxine Users: Retrospective Population-based Study. 61
33793038 2021
46
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. 61
33529725 2021
47
Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent. 61
33315125 2021
48
The relationship between rice consumption and glioma: a case-control study in adults. 61
33727597 2021
49
Guided assembly of cancer ellipsoid on suspended hydrogel microfibers estimates multi-cellular traction force. 61
33412531 2021
50
Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma. 61
33684289 2021

Variations for Brain Cancer

ClinVar genetic disease variations for Brain Cancer:

6 (show top 50) (show all 238)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ALK NM_004304.5(ALK):c.3824G>A (p.Arg1275Gln) SNV Likely pathogenic 18083 rs113994087 GRCh37: 2:29432664-29432664
GRCh38: 2:29209798-29209798
2 PTEN NM_000314.8(PTEN):c.1003C>T (p.Arg335Ter) SNV Likely pathogenic 7833 rs121909231 GRCh37: 10:89720852-89720852
GRCh38: 10:87961095-87961095
3 EGFR NM_005228.5(EGFR):c.865_866delinsAT (p.Ala289Ile) Indel Likely pathogenic 376398 rs1057519887 GRCh37: 7:55221821-55221822
GRCh38: 7:55154128-55154129
4 PIK3CA NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr) SNV Likely pathogenic 376486 rs1057519937 GRCh37: 3:178952073-178952073
GRCh38: 3:179234285-179234285
5 PIK3CA NM_006218.4(PIK3CA):c.1637A>C (p.Gln546Pro) SNV Likely pathogenic 375898 rs397517201 GRCh37: 3:178936095-178936095
GRCh38: 3:179218307-179218307
6 EGFR NM_005228.5(EGFR):c.866C>T (p.Ala289Val) SNV Likely pathogenic 376209 rs149840192 GRCh37: 7:55221822-55221822
GRCh38: 7:55154129-55154129
7 EGFR NM_005228.5(EGFR):c.866C>A (p.Ala289Asp) SNV Likely pathogenic 376396 rs149840192 GRCh37: 7:55221822-55221822
GRCh38: 7:55154129-55154129
8 PIK3CA NM_006218.4(PIK3CA):c.353G>A (p.Gly118Asp) SNV Likely pathogenic 156446 rs587777790 GRCh37: 3:178917478-178917478
GRCh38: 3:179199690-179199690
9 PIK3CA NM_006218.4(PIK3CA):c.3127A>G (p.Met1043Val) SNV Likely pathogenic 376485 rs1057519936 GRCh37: 3:178952072-178952072
GRCh38: 3:179234284-179234284
10 PIK3CA NM_006218.4(PIK3CA):c.3129G>A (p.Met1043Ile) SNV Likely pathogenic 179173 rs121913283 GRCh37: 3:178952074-178952074
GRCh38: 3:179234286-179234286
11 PIK3CA NM_006218.4(PIK3CA):c.1636C>A (p.Gln546Lys) SNV Likely pathogenic 13657 rs121913286 GRCh37: 3:178936094-178936094
GRCh38: 3:179218306-179218306
12 PIK3CA NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu) SNV Likely pathogenic 376487 rs1057519936 GRCh37: 3:178952072-178952072
GRCh38: 3:179234284-179234284
13 PIK3CA NM_006218.4(PIK3CA):c.1636C>G (p.Gln546Glu) SNV Likely pathogenic 13654 rs121913286 GRCh37: 3:178936094-178936094
GRCh38: 3:179218306-179218306
14 EGFR NM_005228.5(EGFR):c.865G>A (p.Ala289Thr) SNV Likely pathogenic 376395 rs769696078 GRCh37: 7:55221821-55221821
GRCh38: 7:55154128-55154128
15 PIK3CA NM_006218.4(PIK3CA):c.1637A>T (p.Gln546Leu) SNV Likely pathogenic 375899 rs397517201 GRCh37: 3:178936095-178936095
GRCh38: 3:179218307-179218307
16 EGFR NM_005228.5(EGFR):c.865_866delinsAA (p.Ala289Asn) Indel Likely pathogenic 376397 rs1057519887 GRCh37: 7:55221821-55221822
GRCh38: 7:55154128-55154129
17 PIK3CA NM_006218.4(PIK3CA):c.1638G>T (p.Gln546His) SNV Likely pathogenic 376491 rs1057519940 GRCh37: 3:178936096-178936096
GRCh38: 3:179218308-179218308
18 TP53 NM_000546.5(TP53):c.404G>T (p.Cys135Phe) SNV Likely pathogenic 376559 rs587781991 GRCh37: 17:7578526-7578526
GRCh38: 17:7675208-7675208
19 TP53 NM_000546.5(TP53):c.833C>A (p.Pro278His) SNV Likely pathogenic 376646 rs876659802 GRCh37: 17:7577105-7577105
GRCh38: 17:7673787-7673787
20 TP53 NM_000546.6(TP53):c.845G>C (p.Arg282Pro) SNV Likely pathogenic 376659 rs730882008 GRCh37: 17:7577093-7577093
GRCh38: 17:7673775-7673775
21 TP53 NM_000546.5(TP53):c.731G>T (p.Gly244Val) SNV Likely pathogenic 376601 rs985033810 GRCh37: 17:7577550-7577550
GRCh38: 17:7674232-7674232
22 TP53 NM_000546.5(TP53):c.711G>A (p.Met237Ile) SNV Likely pathogenic 142714 rs587782664 GRCh37: 17:7577570-7577570
GRCh38: 17:7674252-7674252
23 TP53 NM_000546.5(TP53):c.823T>C (p.Cys275Arg) SNV Likely pathogenic 376584 rs1057519983 GRCh37: 17:7577115-7577115
GRCh38: 17:7673797-7673797
24 TP53 NM_001276697.2(TP53):c.-75T>C SNV Likely pathogenic 376560 rs1057519975 GRCh37: 17:7578527-7578527
GRCh38: 17:7675209-7675209
25 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely pathogenic 13656 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
26 IDH1 NM_001282386.1(IDH1):c.394C>T (p.Arg132Cys) SNV Likely pathogenic 375891 rs121913499 GRCh37: 2:209113113-209113113
GRCh38: 2:208248389-208248389
27 TP53 NM_000546.5(TP53):c.763A>T (p.Ile255Phe) SNV Likely pathogenic 376621 rs1057519995 GRCh37: 17:7577518-7577518
GRCh38: 17:7674200-7674200
28 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu) SNV Likely pathogenic 376655 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
29 TP53 NM_000546.5(TP53):c.713G>C (p.Cys238Ser) SNV Likely pathogenic 376575 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250
30 TP53 NM_000546.5(TP53):c.584T>C (p.Ile195Thr) SNV Likely pathogenic 216077 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
31 TP53 NM_000546.5(TP53):c.395A>G (p.Lys132Arg) SNV Likely pathogenic 376625 rs1057519996 GRCh37: 17:7578535-7578535
GRCh38: 17:7675217-7675217
32 TP53 NM_001276697.2(TP53):c.-57T>C SNV Likely pathogenic 376565 rs1057519978 GRCh37: 17:7578509-7578509
GRCh38: 17:7675191-7675191
33 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly) SNV Likely pathogenic 140821 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
34 TP53 NM_000546.5(TP53):c.818G>C (p.Arg273Pro) SNV Likely pathogenic 231060 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
35 TP53 NM_000546.5(TP53):c.707A>G (p.Tyr236Cys) SNV Likely pathogenic 376693 rs730882026 GRCh37: 17:7577574-7577574
GRCh38: 17:7674256-7674256
36 TP53 NM_000546.5(TP53):c.730G>C (p.Gly244Arg) SNV Likely pathogenic 376602 rs1057519989 GRCh37: 17:7577551-7577551
GRCh38: 17:7674233-7674233
37 TP53 NM_000546.6(TP53):c.722C>G (p.Ser241Cys) SNV Likely pathogenic 177791 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
38 TP53 NM_000546.5(TP53):c.581T>G (p.Leu194Arg) SNV Likely pathogenic 376633 rs1057519998 GRCh37: 17:7578268-7578268
GRCh38: 17:7674950-7674950
39 TP53 NM_001276697.2(TP53):c.-27C>G SNV Likely pathogenic 376641 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
40 TP53 NM_000546.5(TP53):c.518T>C (p.Val173Ala) SNV Likely pathogenic 376017 rs1057519747 GRCh37: 17:7578412-7578412
GRCh38: 17:7675094-7675094
41 TP53 NM_000546.5(TP53):c.374C>T (p.Thr125Met) SNV Likely pathogenic 183748 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
42 TP53 NM_000546.5(TP53):c.734G>C (p.Gly245Ala) SNV Likely pathogenic 265357 rs121912656 GRCh37: 17:7577547-7577547
GRCh38: 17:7674229-7674229
43 TP53 NM_000546.5(TP53):c.638G>T (p.Arg213Leu) SNV Likely pathogenic 376650 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
44 TP53 NM_000546.5(TP53):c.613T>C (p.Tyr205His) SNV Likely pathogenic 376685 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
45 TP53 NM_000546.5(TP53):c.857A>C (p.Glu286Ala) SNV Likely pathogenic 376593 rs1057519985 GRCh37: 17:7577081-7577081
GRCh38: 17:7673763-7673763
46 TP53 NM_001276697.2(TP53):c.-57T>A SNV Likely pathogenic 376567 rs1057519978 GRCh37: 17:7578509-7578509
GRCh38: 17:7675191-7675191
47 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely pathogenic 217293 rs121913275 GRCh37: 3:178936093-178936093
GRCh38: 3:179218305-179218305
48 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu) SNV Likely pathogenic 230253 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
49 TP53 NM_000546.5(TP53):c.824G>A (p.Cys275Tyr) SNV Likely pathogenic 215997 rs863224451 GRCh37: 17:7577114-7577114
GRCh38: 17:7673796-7673796
50 IDH2 NM_001289910.1(IDH2):c.358A>G (p.Arg120Gly) SNV Likely pathogenic 376439 rs1057519906 GRCh37: 15:90631839-90631839
GRCh38: 15:90088607-90088607

Copy number variations for Brain Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 112045 17 37800000 41900000 Gain Brain cancer
2 179187 8 123863081 124055936 Deletion RAF1 Brain cancer
3 205638 6 130400000 131300000 Deletion Brain cancer
4 233881 8 128747764 129113498 Amplification MYC Brain cancer
5 234173 8 131500000 139900000 Amplification KHDRBS3 Brain cancer
6 254105 9 51800000 140273252 Deletion Brain cancer

Expression for Brain Cancer

Search GEO for disease gene expression data for Brain Cancer.

Pathways for Brain Cancer

Pathways related to Brain Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 131)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 TP53 PTEN PIK3R1 NRAS H3-3A EPHB2
2
Show member pathways
13.65 PIK3R1 NRAS H3-3A EPHB2 EGFR CTNNB1
3
Show member pathways
13.62 TP53 PTPN11 PIK3R1 PIK3CA NRAS H3-3A
4
Show member pathways
13.59 PTPN11 PIK3R1 PIK3CA NRAS H3-3A EPHB2
5
Show member pathways
13.45 TP53 PTPN11 PIK3R1 PIK3CA NRAS EGFR
6
Show member pathways
13.38 PIK3R1 NRAS EPHB2 EGFR CTNNB1 BRAF
7
Show member pathways
13.31 TP53 PIK3R1 PIK3CA NRAS EGFR CTNNB1
8
Show member pathways
13.21 TP53 PTPN11 PTEN PIK3R1 PIK3CA EGFR
9
Show member pathways
13.18 TP53 PTEN PIK3R1 PIK3CA NRAS EGFR
10
Show member pathways
13.17 TP53 PTEN PIK3R1 NRAS EGFR BRAF
11
Show member pathways
13.08 TP53 PTEN PIK3R1 PIK3CA NRAS EGFR
12
Show member pathways
13.05 TP53 PIK3R1 PIK3CA NRAS EGFR CTNNB1
13
Show member pathways
13 PTPN11 PTEN PIK3R1 PIK3CA NRAS EGFR
14
Show member pathways
12.99 PTEN PIK3R1 PIK3CA NRAS EGFR CTNNB1
15
Show member pathways
12.97 PTEN PIK3R1 PIK3CA NRAS EGFR BRAF
16
Show member pathways
12.94 PIK3R1 PIK3CA NRAS EGFR BRAF
17
Show member pathways
12.87 PTPN11 PTEN PIK3R1 PIK3CA BRAF
18
Show member pathways
12.82 PTPN11 PIK3R1 PIK3CA NRAS EGFR CTNNB1
19
Show member pathways
12.81 TP53 PTPN11 PTEN PIK3R1 PIK3CA NRAS
20
Show member pathways
12.77 TP53 PIK3R1 NRAS EGFR BRAF
21
Show member pathways
12.76 TP53 PTEN PIK3R1 PIK3CA NRAS EGFR
22 12.75 PIK3R1 PIK3CA NRAS EGFR BRAF
23
Show member pathways
12.74 PIK3R1 PIK3CA NRAS EGFR CTNNB1
24
Show member pathways
12.72 TP53 PTPN11 PTEN PIK3R1 PIK3CA NRAS
25
Show member pathways
12.7 PTPN11 PTEN PIK3R1 PIK3CA NRAS
26
Show member pathways
12.69 PTPN11 PTEN PIK3R1 PIK3CA NRAS EGFR
27
Show member pathways
12.69 TP53 PTPN11 PTEN PIK3R1 PIK3CA NRAS
28
Show member pathways
12.68 TP53 PTPN11 PIK3R1 PIK3CA NRAS EGFR
29
Show member pathways
12.67 PTPN11 PIK3R1 PIK3CA NRAS BRAF
30
Show member pathways
12.64 TP53 PTEN PIK3R1 PIK3CA NRAS EGFR
31 12.64 TP53 PTEN PIK3R1 PIK3CA NRAS EGFR
32
Show member pathways
12.62 PTPN11 PIK3R1 PIK3CA NRAS BRAF